

Mesothelioma: Scientific clues for prevention, diagnosis

Ca-A Cancer Journal for Clinicians

69, 402-429

DOI: [10.3322/caac.21572](https://doi.org/10.3322/caac.21572)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives. <i>Cancer Research</i> , 2019, 79, 5149-5150.	0.4	47
2	From "shift work that involves circadian disruption" to "night shift work". <i>Industrial Health</i> , 2019, 57, 555-556.	0.4	2
3	Lipid metabolism offers anticancer treatment by regulating ferroptosis. <i>Cell Death and Differentiation</i> , 2019, 26, 2516-2519.	5.0	12
4	Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2019, 82, 1088-1102.	1.1	11
5	Comments on Vimercati et al., 2019, "Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: a systematic review and the experience of the Apulia (southern Italy) mesothelioma register". <i>Environmental Health</i> , 2019, 18, 111.	1.7	1
6	Response to the "Letter to the Editor" by Gabor Mezei et al., Comments on Vimercati et al., 2019, "Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: a systematic review and the experience of the Apulia (Southern Italy) mesothelioma register". <i>Environmental Health</i> , 2019, 18, 112.	1.7	0
7	Mesothelioma Driver Genes, Ferroptosis, and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1318.	1.3	4
8	Data mining analysis of the PP2A cell cycle axis in mesothelioma patients. <i>Journal of Cellular Physiology</i> , 2020, 235, 5284-5292.	2.0	3
9	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 655-660.	0.5	25
10	Metabolic rewiring and redox alterations in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2020, 122, 52-61.	2.9	22
11	Nivolumab for the treatment of unresectable pleural mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 109-114.	1.4	11
12	Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25543-25552.	3.3	53
13	Burden of Mesothelioma Deaths by National Income Category: Current Status and Future Implications. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6900.	1.2	18
14	Characterization of Fibrous Mordenite: A First Step for the Evaluation of Its Potential Toxicity. <i>Crystals</i> , 2020, 10, 769.	1.0	14
15	A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma. <i>EBioMedicine</i> , 2020, 61, 103031.	2.7	7
16	AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression. <i>Cancers</i> , 2020, 12, 2757.	1.7	14
17	Biological Mechanisms and Clinical Significance of <i>BAP1</i> Mutations in Human Cancer. <i>Cancer Discovery</i> , 2020, 10, 1103-1120.	7.7	144
18	Malignant peritoneal mesothelioma presenting as a splenic mass. <i>Pathology Research and Practice</i> , 2020, 216, 153273.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097142.	1.4	28
20	The Role of Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma. <i>Thoracic Surgery Clinics</i> , 2020, 30, 461-471.	0.4	2
21	Carbon Nanotubes under Scrutiny: Their Toxicity and Utility in Mesothelioma Research. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4513.	1.3	9
22	Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice. <i>Cancers</i> , 2020, 12, 2136.	1.7	3
23	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. <i>Clinical Lung Cancer</i> , 2021, 22, 361-370.e3.	1.1	8
24	Needles in haystacks: using fast-response LA chambers and ICP-TOF-MS to identify asbestos fibres in malignant mesothelioma models. <i>Journal of Analytical Atomic Spectrometry</i> , 2020, 35, 2231-2238.	1.6	13
25	A Single Liver Metastasis from Pleural Biphasic Mesothelioma. <i>Diagnostics</i> , 2020, 10, 555.	1.3	2
26	Advances with pharmacotherapy for peritoneal metastasis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2057-2066.	0.9	4
27	RNA editing in mesothelioma: a look forward. <i>Open Biology</i> , 2020, 10, 200112.	1.5	4
28	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 559586.	1.5	11
29	Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma. <i>Cancers</i> , 2020, 12, 2430.	1.7	9
30	Foxp3+ Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma. <i>Journal of Immunology</i> , 2020, 205, 2519-2531.	0.4	13
31	P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. <i>Cell Death and Disease</i> , 2020, 11, 748.	2.7	27
32	Genomics and Functional Genomics of Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6342.	1.8	16
33	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	3.2	15
34	Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma. <i>Cell Death Discovery</i> , 2020, 6, 127.	2.0	10
35	Maintaining Equipoise With Maintenance Therapy in Mesothelioma. <i>Clinical Lung Cancer</i> , 2020, 21, 482-484.	1.1	0
36	The Molecular Basis of Malignant Pleural Mesothelioma. <i>Thoracic Surgery Clinics</i> , 2020, 30, 383-393.	0.4	29

#	ARTICLE	IF	CITATIONS
37	Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. , 2020, 8, e000461.		26
38	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. <i>Clinical Cancer Research</i> , 2020, 26, 3819-3830.	3.2	23
39	Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion. <i>BMJ Case Reports</i> , 2020, 13, e231987.	0.2	1
40	Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?. <i>Journal of Thoracic Oncology</i> , 2020, 15, 884-887.	0.5	1
41	Tumour predisposition and cancer syndromes as models to study gene–environment interactions. <i>Nature Reviews Cancer</i> , 2020, 20, 533-549.	12.8	93
42	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. <i>British Journal of Cancer</i> , 2020, 123, 644-656.	2.9	29
43	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
45	Chromosomal rearrangements and their neoantigenic potential in mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S92-S99.	1.3	23
46	Peritoneal mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S120-S132.	1.3	35
47	Mesothelioma developing in carriers of inherited genetic mutations. <i>Translational Lung Cancer Research</i> , 2020, 9, S67-S76.	1.3	19
48	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, S100-S119.	1.3	43
49	BAP1: role in carcinogenesis and clinical implications. <i>Translational Lung Cancer Research</i> , 2020, 9, S60-S66.	1.3	32
50	Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S86-S91.	1.3	17
51	How asbestos and other fibers cause mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S39-S46.	1.3	49
52	SV40 and human mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S47-S59.	1.3	22
53	Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients. <i>Journal of Immigrant and Minority Health</i> , 2020, 22, 1163-1171.	0.8	2
54	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. <i>Frontiers in Oncology</i> , 2019, 9, 1519.	1.3	61
55	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	0.5	51

#	ARTICLE	IF	CITATIONS
56	Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the Universal CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2. <i>Cells</i> , 2020, 9, 888.	1.8	19
57	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. <i>Cancers</i> , 2020, 12, 915.	1.7	1
58	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102949.	2.0	20
59	Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis. <i>Diagnostic Cytopathology</i> , 2021, 49, 606-614.	0.5	8
60	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	0.6	2
61	Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 14-16.	0.5	2
62	Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy. <i>Case Reports in Oncology</i> , 2021, 13, 1483-1489.	0.3	0
63	Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2021, 253, 68-79.	2.1	25
64	Malignant Mesothelioma of the Peritoneum in Women. <i>American Journal of Surgical Pathology</i> , 2021, 45, 45-58.	2.1	11
65	Recent Advances in the Genomic and Proteomic Researches on Mesothelioma: What Are Novel Insights into Mesothelioma Biology?. <i>Respiratory Disease Series</i> , 2021, , 137-149.	0.1	0
66	Genetic Predisposition to Mesothelioma: What Are the Biological Mechanisms and What Are the Clinical Characteristics of These Mesotheliomas?. <i>Respiratory Disease Series</i> , 2021, , 151-165.	0.1	0
67	Bridging the gap between toxicity and carcinogenicity of mineral fibres by connecting the fibre crystal-chemical and physical parameters to the key characteristics of cancer. <i>Current Research in Toxicology</i> , 2021, 2, 42-52.	1.3	19
68	HA Matrix Regulates the Local Synthesis of Hyaluronan in Malignant Pleural Mesothelioma by Modulating HAS3 Expression. <i>Cancers</i> , 2021, 13, 416.	1.7	4
69	Systemic Chemotherapy for Unresectable Pleural Mesothelioma from Front Line to Salvage Treatment: How Can We Treat the Patients Failed to PD-1/PD-L1 Inhibitors?. <i>Respiratory Disease Series</i> , 2021, , 253-266.	0.1	0
70	Biomolecular Pathways in Mesothelioma: What Is New Perspective on Biomolecular Research for Mesothelioma?. <i>Respiratory Disease Series</i> , 2021, , 43-52.	0.1	0
72	Immune checkpoint inhibitors in mesothelioma: a turning point. <i>Lancet, The</i> , 2021, 397, 348-349.	6.3	15
73	Inorganic Fiber Lung Burden in Subjects with Occupational and/or Anthropogenic Environmental Asbestos Exposure in Broni (Pavia, Northern Italy): An SEM-EDS Study on Autoptic Samples. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2053.	1.2	13
74	Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation. <i>Molecular Cancer Research</i> , 2021, 19, 921-931.	1.5	3

#	ARTICLE	IF	CITATIONS
75	Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy“ case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 1039-1046.	1.3	18
76	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 190-197.	5.1	34
77	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 152, 1-6.	0.9	7
78	Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, 44, e272-e274.	0.3	2
79	Association of 13 Occupational Carcinogens in Patients With Cancer, Individually and Collectively, 1990-2017. <i>JAMA Network Open</i> , 2021, 4, e2037530.	2.8	23
80	Ingredients such as trehalose and hesperidin taken as supplements or foods reverse alterations in human TÂcells, reducing asbestos exposure-induced antitumor immunity. <i>International Journal of Oncology</i> , 2021, 58, .	1.4	4
81	Development of the “National Asbestos Profile” to Eliminate Asbestos-Related Diseases in 195 Countries. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1804.	1.2	12
82	Asbestos and Zeolites: from A to Z via a Common Ion. <i>Chemical Research in Toxicology</i> , 2021, 34, 936-951.	1.7	5
83	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 653497.	1.3	8
84	The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma. <i>Journal of Clinical Medicine</i> , 2021, 10, 1034.	1.0	6
85	Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 1513.	1.7	27
86	Effect of IL-15 addition on asbestos-induced suppression of human cytotoxic T lymphocyte induction. <i>Environmental Health and Preventive Medicine</i> , 2021, 26, 50.	1.4	2
87	Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100155.	0.6	3
88	Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. <i>Journal of Thoracic Disease</i> , 2021, 13, 2510-2523.	0.6	18
89	In vitro toxicity of fibrous glaucophane. <i>Toxicology</i> , 2021, 454, 152743.	2.0	11
90	Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	15
91	Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions. <i>Cancers</i> , 2021, 13, 1660.	1.7	8
92	Erionite asbestiform fibres and health risk in Aotearoa/New Zealand: A research note. <i>New Zealand Geographer</i> , 2021, 77, 123-129.	0.4	3

#	ARTICLE	IF	CITATIONS
93	Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells. <i>Journal of Biochemistry</i> , 2021, 170, 317-326.	0.9	2
94	A Systematic Study of the Cryogenic Milling of Chrysotile Asbestos. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4826.	1.3	3
95	â€œOmental Cakeâ€ in a Patient With Asbestosis Leading to the Diagnosis of Malignant Peritoneal Mesothelioma. <i>Cureus</i> , 2021, 13, e15116.	0.2	1
96	Chemo-physical properties of asbestos bodies in human lung tissues studied at the nano-scale by non-invasive, label free x-ray imaging and spectroscopic techniques. <i>Toxicology Letters</i> , 2021, 348, 18-27.	0.4	6
97	Asbestos bodies count and morphometry in bulk lung tissue samples by non-invasive X-ray micro-tomography. <i>Scientific Reports</i> , 2021, 11, 10608.	1.6	2
98	Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. <i>Cancers</i> , 2021, 13, 2445.	1.7	4
99	Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy. <i>Diagnostics</i> , 2021, 11, 841.	1.3	2
100	When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines. <i>Journal of Clinical Medicine</i> , 2021, 10, 2434.	1.0	11
101	Assessment of interferon- β in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3349-3355.	2.0	1
102	Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 148.	0.8	20
103	Fiber burden and asbestos-related diseases: an umbrella review. <i>Gaceta Sanitaria</i> , 2022, 36, 173-183.	0.6	10
104	Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development. <i>Cancer Letters</i> , 2021, 507, 26-38.	3.2	18
105	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. <i>Frontiers in Oncology</i> , 2021, 11, 660039.	1.3	28
106	Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 3291.	1.7	5
107	Immunotherapy in Malignant Pleural Mesothelioma. , 0, , .		0
108	Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation. <i>Lung Cancer</i> , 2021, 157, 30-39.	0.9	10
109	Combination of Plasma-Based Metabolomics and Machine Learning Algorithm Provides a Novel Diagnostic Strategy for Malignant Mesothelioma. <i>Diagnostics</i> , 2021, 11, 1281.	1.3	7
110	The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7416.	1.8	4

#	ARTICLE	IF	CITATIONS
111	Biological basis for novel mesothelioma therapies. <i>British Journal of Cancer</i> , 2021, 125, 1039-1055.	2.9	14
112	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	7.7	222
113	Human Health Hazards Associated with Asbestos in Building Materials. , 2022, , 297-325.		5
114	New Updates of the Imaging Role in Diagnosis, Staging, and Response Treatment of Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 4377.	1.7	11
115	Non-coding RNA regulatory networks in mesothelioma: a narrative review of their implication in innate immune signaling pathways. <i>Precision Cancer Medicine</i> , 0, 4, 23-23.	1.8	0
116	Mesothelioma in immigrants from Turkey: Genes have a minor role. <i>Respiratory Medicine</i> , 2021, 186, 106527.	1.3	1
118	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0
119	Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 750352.	1.6	4
120	Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review. <i>Precision Cancer Medicine</i> , 2021, 4, 27-27.	1.8	15
121	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021, 146, 155622.	1.4	4
122	Characterization and assessment of the potential toxicity/pathogenicity of Russian commercial chrysotile. <i>American Mineralogist</i> , 2021, 106, 1606-1621.	0.9	10
123	Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534499.	1.8	3
125	Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 73-80.	1.4	11
126	BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress. <i>Biochemical Journal</i> , 2019, 476, 3053-3066.	1.7	18
127	Heterozygous germline <i>BLM</i> mutations increase susceptibility to asbestos and mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 33466-33473.	3.3	30
129	The phytohormone forchlorfenuron decreases viability and proliferation of malignant mesothelioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2019, 10, 6944-6956.	0.8	13
130	Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 918-931.	0.9	14
131	Forecast of Malignant Peritoneal Mesothelioma Mortality in Italy up to 2040. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 160.	1.2	4

#	ARTICLE	IF	CITATIONS
132	Emerging Drug Therapies for Mesothelioma. , 0, , .		1
133	BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2021, 13, 5741-5751.	0.6	5
134	The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11452.	1.8	3
135	Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1014.	1.1	5
136	Recent progress and perspectives on the mechanisms underlying Asbestos toxicity. <i>Genes and Environment</i> , 2021, 43, 46.	0.9	14
137	A critical review of the 2020 EPA risk assessment for chrysotile and its many shortcomings. <i>Critical Reviews in Toxicology</i> , 2021, 51, 509-539.	1.9	7
138	MALAT1 promotes malignant pleural mesothelioma by sponging miR-141-3p. <i>Open Medicine (Poland)</i> , 2021, 16, 1653-1667.	0.6	8
139	Malignant Mesothelioma: Asbestos Exposure. , 2020, , 363-378.		0
140	Biomarkers Progress and Therapeutic Implications in Malignant Mesothelioma. , 0, , .		0
141	Current Mesothelioma Treatment and Future Perspectives. , 0, , .		0
142	Genetic Alterations of Malignant Pleural Mesothelima. , 0, , .		0
143	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 373.	0.8	1
144	BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene Å— environment interaction with asbestos. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
145	Characterisation of potentially toxic natural fibrous zeolites by means of electron paramagnetic resonance spectroscopy and morphological-mineralogical studies. <i>Chemosphere</i> , 2022, 291, 133067.	4.2	7
146	Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12868.	1.8	2
147	Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms. <i>Cancers</i> , 2021, 13, 5664.	1.7	16
148	Which ICDâ€9 codes were assigned for malignant mesothelioma in the mortality data in the United States before the ICDâ€10 was introduced?. <i>American Journal of Industrial Medicine</i> , 2021, 65, 143.	1.0	2
149	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11

#	ARTICLE	IF	CITATIONS
150	Malignant pleural mesothelioma: Experience of the Medical Oncology Department of Hassan II Hospital in Fez, Morocco. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2021, 8, 6-11.	0.3	0
151	Acute cytotoxicity of mineral fibres observed by time-lapse video microscopy. <i>Toxicology</i> , 2022, 466, 153081.	2.0	9
152	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	0.9	15
153	Elemental Mapping of Human Malignant Mesothelioma Tissue Samples Using High-Speed LA-ICP-TOFMS Imaging. <i>Analytical Chemistry</i> , 2022, 94, 2597-2606.	3.2	5
154	Metabolomics of a cell line-derived xenograft model reveals circulating metabolic signatures for malignant mesothelioma. <i>PeerJ</i> , 2022, 10, e12568.	0.9	1
155	Favorable response to nivolumab in sarcomatoid malignant pleural mesothelioma: A case report. <i>Current Problems in Cancer Case Reports</i> , 2022, 5, 100138.	0.1	1
156	Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights. <i>Frontiers in Oncology</i> , 2022, 12, 823839.	1.3	5
157	Global Magnitude and Temporal Trend of Mesothelioma Burden Along with the Contribution of Occupational Asbestos Exposure in 204 Countries and Territories from 1990 to 2019: Results from the Global Burden of Disease Study 2019. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
158	Clinical Analysis of 26 Cases of Malignant Peritoneal Mesothelioma. <i>Advances in Clinical Medicine</i> , 2022, 12, 1654-1662.	0.0	0
159	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 75.	3.5	7
160	Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. <i>Cancers</i> , 2022, 14, 981.	1.7	3
161	Current Management and Future Perspective in Pleural Mesothelioma. <i>Cancers</i> , 2022, 14, 1044.	1.7	7
162	Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, 871544.	1.3	0
163	Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach. <i>Journal of Clinical Medicine</i> , 2022, 11, 1659.	1.0	2
164	Geoethical futures: A call for more-than-human physical geography. <i>The Environment and Planning F, Philosophy, Models, Methods and Practice</i> , 2022, 1, 66-81.	0.2	13
165	Treatment of Patients with Malignant Peritoneal Mesothelioma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1891.	1.0	4
166	Hand2 delineates mesothelium progenitors and is reactivated in mesothelioma. <i>Nature Communications</i> , 2022, 13, 1677.	5.8	17
167	Causes and Pathogenesis of Malignant Mesothelioma. , 0, , .		2

#	ARTICLE	IF	CITATIONS
168	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103639.	2.0	13
169	Forchlorfenuron and Novel Analogs Cause Cytotoxic Effects in Untreated and Cisplatin-Resistant Malignant Mesothelioma-Derived Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3963.	1.8	2
170	Malignant pleural mesothelioma: an update. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210129.	0.4	8
171	The emission of natural harmful particulate matters by wind erosion and possible impact areas, Cappadocia province, Central Anatolia, Turkey. <i>Bulletin of Engineering Geology and the Environment</i> , 2022, 81, 1.	1.6	3
172	Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A. <i>Cells</i> , 2021, 10, 3543.	1.8	5
173	An unusual cause of dysphagia. <i>Frontline Gastroenterology</i> , 0, , flgastro-2021-101966.	0.9	0
174	KRAS signaling in malignant pleural mesothelioma. <i>EMBO Molecular Medicine</i> , 2022, 14, e13631.	3.3	12
175	Asbestos-induced mesothelial injury and carcinogenesis: Involvement of iron and reactive oxygen species. <i>Pathology International</i> , 2022, 72, 83-95.	0.6	5
176	Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma. <i>Frontiers in Oncology</i> , 2021, 11, 789244.	1.3	3
177	How Malignant Mesothelioma Was Coded in Mortality Data in Taiwan During Years When the Specific ICD Code Was Not Available?. <i>Clinical Epidemiology</i> , 2021, Volume 13, 1135-1140.	1.5	0
178	Characterization of Fibrous Wollastonite NYAD G in View of Its Use as Negative Standard for In Vitro Toxicity Tests. <i>Minerals (Basel, Switzerland)</i> , 2021, 11, 1378.	0.8	4
180	Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma. <i>Biomaterials</i> , 2022, 285, 121534.	5.7	5
181	Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review. <i>Thorax</i> , 2023, 78, 409-417.	2.7	6
183	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	0.5	44
184	BAP1 shapes the bone marrow niche for lymphopoiesis by fine-tuning epigenetic profiles in endosteal mesenchymal stromal cells. <i>Cell Death and Differentiation</i> , 2022, 29, 2151-2162.	5.0	4
185	Malignant peritoneal mesothelioma literature review: past, present, and future. <i>Digestive Medicine Research</i> , 0, 5, 29-29.	0.2	3
186	Fibrous Ferrierite from Northern Italy: Mineralogical Characterization, Surface Properties, and Assessment of Potential Toxicity. <i>Minerals (Basel, Switzerland)</i> , 2022, 12, 626.	0.8	4
187	Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
188	NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
189	Update of pathological diagnosis of pleural mesothelioma using genomicâ€based morphological techniques, for both histological and cytological investigations. <i>Pathology International</i> , 2022, 72, 389-401.	0.6	5
190	BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability. <i>Cell Death and Differentiation</i> , 2022, 29, 2381-2398.	5.0	10
191	The burden of pneumoconiosis in China: an analysis from the Global Burden of Disease Study 2019. <i>BMC Public Health</i> , 2022, 22, .	1.2	17
192	The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. <i>Current Oncology Reports</i> , 2022, 24, 1413-1423.	1.8	1
193	YAP1 is essential for malignant mesothelioma tumor maintenance. <i>BMC Cancer</i> , 2022, 22, .	1.1	10
194	Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold. <i>Journal of Clinical Medicine</i> , 2022, 11, 3225.	1.0	0
195	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
196	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
197	Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
198	Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
200	Sera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	1
201	Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development. <i>Vaccines</i> , 2022, 10, 1168.	2.1	1
202	Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 8284-8290.	0.3	1
204	The Multifaceted Roles of Autophagy in Infectious, Obstructive, and Malignant Airway Diseases. <i>Biomedicines</i> , 2022, 10, 1944.	1.4	3
205	Does the Amount of Asbestos Exposure Influence Prognosis?. <i>Journal of Thoracic Oncology</i> , 2022, 17, 949-952.	0.5	0
206	Malignant peritoneal mesothelioma. <i>American Journal of the Medical Sciences</i> , 2023, 365, 99-103.	0.4	5
207	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 49-71.	157.7	23

#	ARTICLE	IF	CITATIONS
208	Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells. Thoracic Cancer, 0, , .	0.8	2
209	Potential Toxicity of Natural Fibrous Zeolites: In Vitro Study Using Jurkat and HT22 Cell Lines. Minerals (Basel, Switzerland), 2022, 12, 988.	0.8	3
210	Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from 1990 to 2019: Results from the Global Burden of Disease Study 2019. Critical Reviews in Oncology/Hematology, 2022, 179, 103821.	2.0	9
211	Pleural Mesothelioma: Unexpected Finding in a Young Man. Journal of Gandhara Medical and Dental Science, 2022, 9, .	0.1	0
212	Malignant Mesothelioma <i>In Situ</i> : A Controversial Diagnostic Entity: A Review. , 0, , .		0
213	Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Modern Pathology, 2022, 35, 1888-1899.	2.9	2
214	Blood cell <i>DNA</i> methylation biomarkers in preclinical malignant pleural mesothelioma: The <i>EPIC</i> prospective cohort. International Journal of Cancer, 2023, 152, 725-737.	2.3	4
215	Heterogeneous <i>RNA</i> editing and influence of <i>ADAR2</i> on mesothelioma chemoresistance and the tumor microenvironment. Molecular Oncology, 2022, 16, 3949-3974.	2.1	2
216	BAP1 in cancer: epigenetic stability and genome integrity. Discover Oncology, 2022, 13, .	0.8	5
217	Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clinical and Research Reports, 2022, 3, 100430.	0.6	2
218	Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma. Carcinogenesis, 0, , .	1.3	1
219	Global geological occurrence and character of the carcinogenic zeolite mineral, erionite: A review. Frontiers in Chemistry, 0, 10, .	1.8	2
220	The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016â€“2030. Translational Lung Cancer Research, 2022, 11, 2403-2411.	1.3	2
221	Malignant peritoneal mesotheliomaâ€”a diagnostic challenge. Journal of Surgical Case Reports, 2022, .	0.2	0
222	Complexity of progranulin mechanisms of action in mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
223	BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene, 2023, 42, 572-585.	2.6	4
225	Cancers Attributable to Modifiable Risk Factors: A Road Map for Prevention. Annual Review of Public Health, 2023, 44, 279-300.	7.6	8
226	Asbestos fibers promote iron oxidation and compete with apoferritin enzymatic activity. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2023, 86, 69-73.	1.1	4

#	ARTICLE	IF	CITATIONS
227	Asbestos Exposure and Malignant Pleural Mesothelioma: A Systematic Review of Literature. Portuguese Journal of Public Health, 2022, 40, 188-202.	1.7	1
228	A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment. Scientific Reports, 2023, 13, .	1.6	2
229	Serum diagnostic markers for malignant pleural mesothelioma: a narrative review. Translational Cancer Research, 2022, 11, 4434-4440.	0.4	2
230	Misdiagnosis of Peritoneal Mesothelioma as Ovarian Carcinoma in a Young Female: "Who is Gatecrashing Your Masquerade Party?" Indian Journal of Gynecologic Oncology, 2023, 21, .	0.1	0
231	Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	7
232	BAP1 is a novel regulator of HIF-1 α . Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	6
233	Causes of Cancer and Mechanisms of Carcinogenesis. , 2023, , 229-279.		0
234	Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma. Cancers, 2023, 15, 662.	1.7	4
235	Current causes of mesothelioma: how has the asbestos ban changed the perspective?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 0, , .	0.2	1
236	A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment. International Journal of Molecular Sciences, 2023, 24, 6689.	1.8	2
237	New pathogenic germline variants identified in mesothelioma. Lung Cancer, 2023, 179, 107172.	0.9	1
238	Peritoneal Mesothelioma"An Update. Advances in Anatomic Pathology, 2023, 30, 262-274.	2.4	3
239	The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences, 2023, 24, 2874.	1.8	0
240	A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma. Pathology, 2023, 55, 449-455.	0.3	3
241	Targeting BAP1 with small compound inhibitor for colon cancer treatment. Scientific Reports, 2023, 13, .	1.6	1
242	Incidence and mortality from malignant mesothelioma 1982"2020 and relationship with asbestos exposure: the Australian Mesothelioma Registry. Occupational and Environmental Medicine, 2023, 80, 186-191.	1.3	8
243	Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. European Respiratory Review, 2023, 32, 220174.	3.0	5
244	Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma. Cell Reports Medicine, 2023, 4, 100938.	3.3	4

#	ARTICLE	IF	CITATIONS
245	Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. <i>Journal of Thoracic Oncology</i> , 2023, 18, 792-802.	0.5	17
246	Rare recurrence of malignant mesothelioma spreading to the perineum. <i>BMJ Case Reports</i> , 2023, 16, e252441.	0.2	0
248	Defining and targeting tumor-associated macrophages in malignant mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	3
249	Thrombocytosis as a paraneoplastic syndrome in metastatic malignant peritoneal mesothelioma of biphasic morphology mimicking ovarian adenocarcinoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.2	1
250	Second Primary Cancers in a Population-Based Mesothelioma Registry. <i>Cancers</i> , 2023, 15, 1746.	1.7	0
251	Multioomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. <i>Nature Genetics</i> , 2023, 55, 607-618.	9.4	18
252	Multistage carcinogenesis: Impact of age, genetic, and environmental factors on the incidence of malignant mesothelioma. <i>Environmental Research</i> , 2023, 230, 114582.	3.7	4
253	An updated review of diffuse mesothelioma of the pleura – A sentinel health event of potential elongate mineral particle pathogenicity. <i>Environmental Research</i> , 2023, 230, 115608.	3.7	1
254	Mechanisms and shapes of causal exposure-response functions for asbestos in mesotheliomas and lung cancers. <i>Environmental Research</i> , 2023, 230, 115607.	3.7	3
255	Developing sustainable patient and public involvement in mesothelioma research: multi-method exploration with researchers, patients, carers, and patient organisations. <i>Research Involvement and Engagement</i> , 2023, 9, .	1.1	2
256	BAP1 as a guardian of genome stability: implications in human cancer. <i>Experimental and Molecular Medicine</i> , 2023, 55, 745-754.	3.2	6
257	Malignant and borderline mesothelial tumors of the pleura. , 2024, , 755-792.		1
258	Sequential multi-parametric MRI in assessment of the histological subtype and features in the malignant pleural mesothelioma xenografts. <i>Heliyon</i> , 2023, 9, e15237.	1.4	2
259	Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
260	Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma. <i>Cancer Medicine</i> , 0, , .	1.3	0
261	Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
280	Asbestos, Mining, Mesothelioma, and Lung Cancer. , 2023, , 245-265.		0
283	An overview on multimodal imaging for the diagnostic workup of pleural mesothelioma. <i>Japanese Journal of Radiology</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
296	Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors. Targeted Oncology, 0, , .	1.7	0
302	Talc and Malignant Mesothelioma. , 0, , .		0